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Bio-repositories and databases for biomedical research enable the efficient community-wide sharing of
reagents and data. These archives play an increasingly prominent role in the generation and
dissemination of bioresources and data essential for fundamental and translational research. Evidence
suggests, however, that current funding and governance models, generally short-term and nationally
focused, do not adequately support the role of archives in long-term, transnational endeavours to make
and share high-impact resources. Our qualitative case study of the International Knockout Mouse
Consortium and the International Mouse Phenotyping Consortium examines new governance
mechanisms for archive sustainability. Funders and archive managers highlight in interviews that
archives need stable public funding and new revenue-generation models to be sustainable. Sustainability
also requires archives, journal publishers, and funders to implement appropriate incentives, associated
metrics, and enforcement mechanisms to ensure that researchers use archives to deposit reagents and
data to make them publicly accessible for academia and industry alike.Introduction
The biomedical sciences are now generating reagents and data in
rapidly increasing volumes that require proportional modes of
archiving and dissemination [1]. Increased sharing minimizes
duplication, makes research reagents more cost-effective, and
enables novel and follow-on research as well as independent
testing of published results [2]. International agreements (e.g.
the 1996 Bermuda Agreement and the 2003 Fort Lauderdale
Agreement) and several funding agency policies on sharing data
and materials (e.g. the Data Sharing Policy of the National Insti-
tutes of Health (NIH) of the US [3] and the Biotechnology and
Biological Sciences Research Council (BBSRC, UK) [4]) encourage
the non-restrictive dissemination and onward use of publicly-
funded research outputs. Some journals also have comprehensive
sharing requirements [5,6]. Community-wide resource sharing
is facilitated by accessible, stable, and well-funded repositories
and databases [1], which are archives responsible for receipt,Corresponding author: Bubela, T.M. (tbubela@ualberta.ca)
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280 1871-6784/ 2015 The Authors. Published by Elsevier B.V. This is an omaintenance, and distribution of materials and data, respective-
ly. We recognize, however, that there are structural and function-
al differences, as well as linkages, between archives of biomaterials
and of data.
Archives are central to the creation of ‘research commons’
within which research reagents, data and other outputs are shared
in a ‘pre-competitive,’ often collaborative space [2,7–9]. Research
commons are supported by governance mechanisms that promote
a cycle of deposit, withdrawal, modification, and re-contribution
of materials and data, creating a ‘network effect’ where the value of
an archive increases with use [1]. Elsewhere, we have explored the
benefits of and incentives for collaborations in mouse model
research [8,10,11]. Here, we explore governance mechanisms that
may better promote these activities and sustain archives for the
community-level sharing of reagents and data, using research on
mouse models of human disease as an exemplar for other research
communities.
The use of standardized model organisms in basic and pre-
clinical research has been instrumental to our understanding ofhttp://dx.doi.org/10.1016/j.nbt.2015.10.002
pen access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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diseases. Communities using these reagents have developed
archives to enhance sharing and to build a communitarian ethos
[1]. For example, key databases have community-integrative
effects by compiling, systematizing, and disseminating informa-
tion on key model species. Examples include The Arabidopsis
Information Resource (TAIR) for the plant model thale cress
(Arabidopsis thaliana) and Mouse Genome Informatics (MGI) for
Mus musculus [12]. The mouse-model community has well-estab-
lished norms for sharing infrastructure, use of standardized mod-
els, and collaborative ethos and practice [10].
Historically, archives for mouse resources were developed to
distribute materials and aggregate data from individually funded
projects. For example, in response to community demands, the
Jackson Laboratory (JAX) became one of the first animal reposito-
ries in the 1930s and was established as a frozen embryo repository
in 1979 [13]. The Harwell Frozen Embryo and Sperm Archive
(FESA; http://www.har.mrc.ac.uk/services/biological-services/
genetically-altered-line-archives) was founded in the mid-1970s
to protect valuable mouse strains and to distribute mice amongst
UK scientists. The current trend, however, is to expand operations
of public archives to support large-scale consortia for high-
throughput generation of research reagents. These large-scale
efforts involve transnational networks of collaborating research
institutions, funders, archives, and end users. Archives are key
linking nodes in these large networks. For example, the Biobank-
ing and Biomolecular Resources Research Infrastructure (BBMRI)
aims to link European biobanks in a federated hub-and-spoke
model [14,15]. The ELIXIR (European Life-sciences Infrastructure
for Biological Information) initiative aims to support the integra-
tion and use of life-science research data generated across Europe,
with the European Bioinformatics Institute (EBI) acting as a data
repository for a series of large international projects, such as
ENCODE [16,17]. In mouse functional genomics, archives are
crucial to the efforts of (1) the International Knockout Mouse
Consortium (IKMC; http://www.mousephenotype.org/about-
ikmc) to knockout (inactivate by replacement or disruption of
DNA sequences) every protein-coding mouse gene and (2) of the
International Mouse Phenotyping Consortium (IMPC; http://
www.mousephenotype.org/) to characterize IKMC mouse strains
using standardized protocols [18].
Funding agreements for the IKMC and IMPC directed that
resources generated by the projects should be accessible beyond
the initial funding term. Accessibility, however, is closely linked
to the long-term sustainability of the archives housing and dis-
seminating resources [1,19]. In a commons framework, resource
sustainability requires governance supporting broad-based par-
ticipation in making and using community archives [7]. In addi-
tion, legal structures and funding mechanisms must support the
transnational and long-term nature of resource-generating initia-
tives, exemplified by the IKMC and IMPC. Such transnational
partnerships have an unprecedentedly broad scope of operations
and service and require concomitantly expanded skill-sets, tech-
nical development, and budgets. Unfortunately, existing funding
and governance structures remain limited in time and jurisdic-
tion, posing a challenge for archive sustainability [15]. Large-scale
archiving initiatives urgently require transnational inter-funder
policies and formal agreements, long-term funding, and legalagreements enabling such support. However, research gover-
nance remains parochial, ‘nationally orientated and based on
the ‘‘one researcher, one project, one jurisdiction’’ model’ [14:
377]. Our case study of mouse functional genomics identifies
governance mechanisms that may sustain archives and strength-
en their performance as infrastructures in a collaborative and
globally networked research milieu.
Whilst we concentrate in this paper on the archiving and
distribution of mouse-related research materials, many of the same
problems of sustainability and governance also apply to data
resources. Where appropriate we discuss some data resource solu-
tions that are currently being implemented, as potential solutions
to the problems of bioresource sharing. There are, however, sig-
nificant differences, which affect models of governance and fund-
ing. For example issues of intellectual property and licensing are
now rarely a problem with large data resources, and although there
exist subscription models, such as the Human Gene Mutation
Database (HGMD) [20], which treats its data as proprietary in a
time-limited fashion, much data are currently freely available and
are generally curated from public resources. International data
distribution and federation are also much easier with databases
than bioresources, and many of the major constraints and chal-
lenges for bioresource repositories do not exist for data.
Bioresource centres are, additionally, much more subject to the
impact of disruptive technologies, which affects long term viabili-
ty. For example, the BACPAC repository of artificial chromosomes
was heavily used until the advance in DNA sequencing technolo-
gies reduced use to the extent that the repository has had to
change its emphasis to remain viable. The ADDGENE (http://
www.addgene.org) repository of plasmids, on the other hand,
has a sufficiently wide remit, low archiving and access costs to
make it one of the most flexible and successful bioresource reposi-
tories [21]. In the mouse field the recent development of CRISPR
(Clustered Regularly Interspaced Short Palindromic Repeats) for
genome editing [22] potentially provides challenges to resource
centre business models and is discussed in depth below.
The following sections describe the background of our case
study, our use of qualitative methods, and our key findings on
(1) gaps between institutional funding policies and the aims,
activities and needs of archives; (2) governance mechanisms
and business models to promote archive use and sustain them
in the long term.
Background of the case study – the IKMC and the IMPC
The IKMC was launched in 2007 to generate mutants for all
protein-coding genes in mouse embryonic stem cells (mESCs)
from the mouse strain C57BL/6N. The IKMC mission was to
provide ‘a core public archive of ES cell clones on a single, uniform,
genetic background, each clone carrying an engineered mutation
in a different gene’ and ‘to extract biological insights from this
resource.. . .’ [23: 581]. There were several considerations behind
the ambitious systematic effort to generate mouse ‘knockouts’ for
biomedical research. First, the mouse is a valuable animal model in
biomedical research owing to its small size, low maintenance cost
relative to larger animal models, genetic similarity to humans,
amenability to genetic modification and analysis, and availability
of inbred lines. Second, prior hypothesis-driven knockout studies
did not provide sufficient, unbiased, coverage of both genome andwww.elsevier.com/locate/nbt 281
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function [24]. Third, before the advent of next generation se-
quencing, attempts at saturation mutagenesis of the mouse ge-
nome with chemical mutagens were slow and expensive, requiring
extensive breeding programmes to identify mutations [25].
Key research centres in the United States (US), continental
Europe, the United Kingdom (UK), and Canada launched the
IKMC effort, using gene targeting and, to lesser extent, gene
trapping [26].1 The IKMC included the KnockOut Mouse Project
(KOMP) funded by the National Institutes of Health (NIH, US),
European Conditional Mouse Mutagenesis Program (EUCOMM)
funded by the EC, and the North American Conditional Mouse
Mutagenesis Project (NorCOMM) funded by Genome Canada
(GC) [23,24,27,28]. By 2012, the IKMC had generated more than
17,400 ES cell clones, which could be ‘readily transferred between
laboratories and across international boundaries’ [23: 581] and
from which large-scale production centres have generated more
than 1700 mouse strains, most of them conditional knockouts,
frozen as sperm [18,28]. Frozen sperm is a low-cost alternative to
embryo-freezing; sperm can easily be transported on dry-ice,
avoiding liquid nitrogen or live-mice shipments.
In 2011, the IMPC was established to generate a complete
phenotypic profile for mice derived from the knockout ES cells
of the IKMC, producing an ‘encyclopedia of mammalian gene
function’ [18]. The IMPC’s ‘systematic phenotyping’ of IKMC
mouse strains investigates the pleiotropic functions and effects
of genes in physiology and development and how genetic muta-
tions are associated with diseases [29]. Running from 2011 until
2021, the IMPC’s high-throughput generation of materials and
data, with community-wide relevance, represents greatly en-
hanced scale, quality, and potential impact compared to earlier
small-scale production and phenotyping efforts [30,31]. Aiming
for community consensus in its efforts, the IMPC actively elicits
inputs from researchers on priorities (e.g. disease area) for knock-
out mouse production and phenotyping [32: 10]. Through the UK
MRC (Medical Research Council) Mouse Network (https://
mrcmousenetwork.har.mrc.ac.uk/), the IMPC coordinates with
researchers interested in specific domains to deliver mice for more
detailed phenotyping and assessment.
The IMPC’s standardized phenotyping screens cover diverse
areas, including behaviour, bone, and muscle development; neu-
rology; vision; haematology; immunology and allergy; cardiovas-
cular and lung function; energy metabolism; and pathology
[32,33]. The protocols have been developed from earlier efforts
of the Wellcome Trust Sanger Institute Mouse Genetics Pro-
gramme (WTSI MGP) (http://www.sanger.ac.uk/ science/
collaboration/mouse-resource-portal), and the European Mouse
Disease Clinic (EUMODIC) project (http://www.eumodic.org/).
The EC-funded EUMODIC was the first internationally coordinat-
ed, large-scale phenotyping effort and was comprised of four
mouse phenotyping centres (MRC Harwell, WTSI, the Institut1While gene trapping costs less than gene targeting, it is random and not
applicable to all genes. Gene targeting works with most genes and, more
importantly, can be used to produce ‘conditional’ knockouts, with effects that
can be activated when required in specific tissues or at specific times, allowing
greater experimental flexibility and avoiding embryonic or perinatal animal
death, common with homozygous knockouts [23,26].
282 www.elsevier.com/locate/nbtClinique de la Souris (ICS; Mouse Clinical Insitute, MCI) Stras-
bourg, and the Helmholtz Zentrum Munich German Mouse Clinic
(GMC)). These centres are founder-partners in the IMPC.
The IMPC high-throughput model requires participating cen-
tres to phenotype a minimum of 100 lines annually. Thus part-
nership is possible between centres with the required capacity to
meet targets, that is, with high health status animal facilities,
transgenic laboratories, phenotyping platforms, trained staff,
and operating funds. Thus the IMPC involves major mouse genet-
ics centres, archives (repositories and databases), live-mouse hous-
ing facilities, and leading funders in Europe, the US, Canada, and
more recently, China, Japan, Korea and Australia (Table A.1 and
Figure A.1). IMPC production and phenotyping centres generate
vectors, live mice, and phenotyping data using the IKMC’s mESC
stocks. Dedicated mouse facilities at production and phenotyping
centres provide closely controlled housing for live mice bred from
repository strains for phenotyping experiments [34]. Repositories
process and distribute mouse materials (sperm, embryos, and
tissue) and live mice; databases disseminate phenotyping data,
both amongst consortium partners and to end-users through a
centralized open-access portal (https://www.mousephenotype.
org/data/search) [35].
Supplementary Table A.1 and Figure A.1 related to this article
can be found, in the online version, at http://dx.doi.org/10.1016/j.
nbt.2015.10.002.
The participating repositories (e.g. the European Mouse Mu-
tant Archive (EMMA) network and the US-based KOMP Reposi-
tory) are transnational in scope, serving individual research
groups in different countries as well as high-throughput projects
such as the IKMC and IMPC. This versatility is made possible by
their extensive technical and human resources. Specialized
teams employ standard methods to manage archives and colo-
nies, to provide information technology support (collecting,
preparing, and disseminating phenotyping data), and to deliver
services (handling customer queries, tracking usage, legal agree-
ments, material transfers, finances, communications, and
outreach).
The archives’ participation in high-throughput resource gener-
ation requires coordination across locations and the standardiza-
tion of production, phenotyping protocols, and data reporting
formats. Such coordination and standardization are key to the
generation, processing, archiving, and dissemination of data and
materials within the consortia and to end-users [35]. Shared stan-
dards enable robust integration of activities of transnational cen-
tres for mouse strain production and phenotyping as well as data
processing and dissemination. This degree of standardization and
specialization is in marked contrast to small institutional archives,
often run by researchers themselves. Similarly, the live mouse
facilities serving the IMPC, with their expanded and dedicated
spaces, specialized staff, and enhanced equipment and security,
are larger in scale than most small university facilities. Expanded
mouse facilities optimize use of time, space, and resources by
consolidating animal housing with research spaces under one
roof. Centralization of functions and higher-density mouse hous-
ing allow researchers to fully phenotype more mouse strains in
shorter time periods, achieving higher throughput. Close moni-
toring of the stand-alone buildings reduces risks of contamination
and colony loss [34]. While smaller archives fill a valuable niche
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consortia, we focus here on archives that support high-throughput
endeavours.
IMPC partners form a confederation through a formal memo-
randum of understanding (MoU) [32,36]. The IMPC’s governance
structures are conditioned by the fact that the research and fund-
ing partners operate in diverse jurisdictions. While a loosely
federated structure may accommodate some jurisdictional diver-
sity, consortium partners may find it difficult to agree on common
legal terms for distribution of materials to end-users or even
amongst consortium members [11]. Additionally, there is a divide
between the transnational aspects of the Consortium and the
funding by national agencies for most members. For example,
the governments of Australia and Japan support the participation
of the Australian Phenomics Network (APN) and the RIKEN Bior-
esource Center (RIKEN BRC), respectively. Transnational funding
is available to relatively few partners, such as the WTSI, which
receives funding from the NIH and also the UK Wellcome Trust
[32,37]. Indeed the IMPC Business Plan acknowledges that while
‘funding for mouse production centres is likely to be granted by
individual funding agencies, there is a need to ensure clearly
coordinated funding for the centralized informatics activity’
[32: 25].
Methods
Between August 2012 and November 2013, we obtained primary
data from in-depth semi-structured interviews of (1) representa-
tives of leading biomedical research funders; (2) managers of
repositories and databases; and (3) managers of mouse facilities.
In designing the interview guides, we consulted Canadian archive
managers and drew on peer-reviewed articles, policy briefs, news
reports, and organizational websites. Questions focused on gover-
nance and best practices for sustaining archives and strengthening
research commons.
Recruitment strategy and intake
We invited participants on the basis of their publication record,
institutional affiliations, and role in the IKMC and IMPC. We
recruited 15 archive managers (9 repositories and 6 databases), 6
mouse facility managers, and 8 funders. Participants were located
in the US, Canada, Europe, Australia, and Japan.
Recording and analysis of data
Interviews were 45–60 min long, conducted over telephone.
Archive and facility managers described (1) their professional
roles; (2) technical aspects of colony and archive management,
archiving, and distribution; (3) funding and business models of
archives; (4) effects of funding on archive efficiency and services
to users; and (5) challenges and solutions in attracting users and
funding. Funders described (1) their agencies’ roles in support-
ing research infrastructures; (2) challenges of long-term trans-
national funding for archives; (3) measures to enhance public
deposits of research output; and (4) challenges in enforcing
open-access policies. We augmented interview data with docu-
mentary analyses.
We anonymized transcripts and organized and analysed data
for salient themes, or ‘codes,’ using NVivo 10 (QSR Internation-
al) qualitative analysis software and the analytical method of‘constant comparison’, involving iterative and linked data collec-
tion and analysis [38]. We compared transcripts to identify themes
in initial interviews. We then explored these themes in subsequent
interviews. We also re-analysed earlier transcripts to incorporate
themes, perspectives, and information emerging from later inter-
views. Coding began with describing basic themes, or ‘open’ codes
(e.g. ‘Locations, networks and setup’; ‘Funding sources’). Next, we
integrated open codes into ‘axial’ codes describing relationships,
interactions, and consequences presented in our results (e.g.
‘Large-scale research infrastructure lacks sustained public fund-
ing’). We stopped coding when analysis yielded no new themes.
We checked quotes to ensure our retention of speakers’ intent and
reviewed codes for appropriateness. We shared our findings with
our informants, four of whom provided critical feedback and
refined our analyses, particularly of European initiatives for infra-
structure development, implications of novel genome-editing
technologies, and challenges of archiving and distributing mouse
lines in a federated system.
Below, we present interview excerpts with alphanumeric codes
representing quoted funders (e.g. F#1) and managers of reposito-
ries (e.g. R#1), mouse facilities (e.g. AF#1), and databases (e.g.
D#1). We use square parentheses around inserted explanations
[no italics], condensed transcript segments [italics], and concealed
identities [no italics].
Ethics
The Research Ethics Office of the University of Alberta approved
our study. We protected identities of participants and maintained
data in secure university locations. We clarified our aims and
methods to participants, who provided signed consent and agreed
to the publication of anonymized data.
Limitations
The small sample size, compared to a survey, and focus on the
mouse model community may limit the generalizability of our
study. However, our data accord with literature on other model
organism communities, and mice are the model most used in
biomedical research. Further, the sample size reflects norms for
qualitative studies and our analyses reached thematic saturation.
While qualitative analyses involve subjective data selection and
interpretation, our analyses were validated by expert informants to
yield a robust account of issues in archive governance and sus-
tainability.
Results
We find that archive funding rests on institutional infrastructure
funding and user-derived fee-for-service income. Both these
sources are themselves dependent on complex contingencies.
Institutional funding depends on policies of national funders,
which experience other demands for limited funds. Income from
user fees depends on level of archive use, which, in turn, depends
on the quality of its resources, its governance structures, and legal
constraints on operations. Costs of deposit and withdrawal need to
be balanced against the scientific value of the resource. To justify
long term sustainability, archives need to be used and develop
metrics to demonstrate the impact of that use – institutional
funders should prioritize only those archives that can demonstrate
use and impact.www.elsevier.com/locate/nbt 283
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While large-scale infrastructure needs stable support, funding
models are rarely designed to meet that need. Funders may
provide some ‘seed funding’ but no long-term support for infra-
structure development. Funders prioritize research project fund-
ing over long-term investments in infrastructure and in a
constrained funding environment, large investments in infra-
structure are seen to divert funds from investigator-initiated
research [39].
While there are various mechanisms to help a resource up,
there are not so many for maintaining it. [F#5]
Most CIHR [Canadian Institutes of Health Research;
principal Canadian funder of academic biomedical re-
search] funding is for project-based research. Large pay-
ments to foundations like Canada Foundation for
Innovation [CFI; main Canadian infrastructure funding
initiative] to build infrastructure put greater burden on
agencies covering project-based funding. [F#2]
As a result, the development and operation of research infra-
structure rely on multiple funding sources within an unpredictable
public funding environment.
Resources get core-operating funding from diverse federal
and provisional agencies. They have quite the patchwork
puzzle to assemble to sustain their core operations. [F#2]
The CFI doesn’t have a regular funding cycle. It launches
new competitions when it receives funds from the federal
government. So it’s hard for researchers to plan when to
submit infrastructure funding proposals. [F#1]
Archives and animal facilities struggle to secure long-term
funding. Short-term funding cycles, geared to shorter project lives,
and shifts in national and institutional funding priorities threaten
development and retention of expertise, physical locations, and
equipment. Shortfalls in these areas, in turn, affect quality of
operations and services.
Most funding cycles now are the relatively short term
project-based model. In that scenario, even five years is
very long. A resource needs consistent core funding for a
decade plus to ensure its capacity to send data or materials
to researchers. Repositories need that classic aid-based
funding from some government-related organization that
commits to developing and maintaining a resource without
time limit on the funding, which would continue so long as
the resource justifies its need. [F#2]
The number of mouse strains that we maintain has been
increasing annually. We will need to renew [facilities
and equipment]. However, government support is de-
creasing across Japan. Our challenge is to minimize
the rate of this decrease by negotiation with the govern-
ment. [R#5]284 www.elsevier.com/locate/nbtOur repository infrastructure is 100 per cent subsidized by
[research institution]. As budgets change, there is no guar-
antee of continued support. [R#2]
Large archives inevitably have higher maintenance and opera-
tional costs than small-scale equivalents, although there are econ-
omies of scale for the system as a whole. Salaries dominate budgets
because skilled personnel are essential to maintain service quality.
Funding shortfalls limit the availability of equipment and person-
nel, such as liquid nitrogen for cryopreserving mouse strains and
personnel for monitoring colony health. Funding shortages or
decreased usage necessitate hard choices between workforce
reductions that affect service quality and compensatory price
increases that may discourage users.
Being a larger facility with specialized staff and equip-
ment, we can take on projects for researchers in other
locations in Australia. But there’s also a high cost with
[specialized] infrastructure. [AF#2]
Funding affects our staff continuity. It takes six months to
a year to get new staff trained and comfortable in their
roles. The IMPC grants are short term. If these funding
streams don’t come through, we have to lay staff off. That
affects our capacity and throughput. [R#3]
Replacing skilled staff can take several months. Backup
persons could continue production but it would take three
or four months instead of two. [R#1]
If we don’t get enough funding or if we can’t sell enough
materials, we will need to either increase the prices or
reduce the workforce. We will probably still have the same
materials but with a different price or reduced workforce, it
may take longer to fulfil services and sales. [R#1]
Archives operate transnationally; funding is national
The nationally bounded nature of funding policies and priorities is
a problem for large archives with transnational services. Funders
find it difficult to harmonize policies and priorities to support
archives in distinct jurisdictions but with networked operations.
The emerging thing is work in an international consortium
model. But we’re challenged to contribute funds to reposi-
tory efforts outside the country when scientifically and
administratively it might make sense. We have had dis-
cussions around cross-funding agreements to support these
platforms. There is no formalized process in place, but that
conversation is increasing. [F#4]
Developments in Europe hold some promise of sustainable
funding models for distributed research infrastructures. In 2002
the European Strategy Forum on Research Infrastructures (ESFRI;
http://ec.europa.eu/research/infrastructures/index_en.cfm?
pg=esfri) was launched, bringing together representatives of EU
Member States and Associated States, and the EC, to support
coherent and strategic policy-making on European research infra-
structures. Another ESFRI objective was to facilitate multilateral
initiatives towards the better use and development of European
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els from the ESFRI aim to address the limitations of short-term
project based funding of research infrastructures. ESFRI prioritizes
infrastructure projects for support and publishes its recommenda-
tions in ESFRI Roadmap reports. Prioritized projects are eligible to
apply for EC funding in response to specific calls.
The first ESFRI Roadmap included 35 infrastructures across all
scientific disciplines, among them, the INFRAFRONTIER infra-
structure, which aims to increase capacities for production, archiv-
ing, distribution and phenotyping of mouse models [40]. In a
preparatory phase a business plan was developed for the INFRA-
FRONTIER research infrastructure and led to the formation of a
transnational legal entity funded by stakeholders. On 11 April
2013, INFRAFRONTIER, centred at the Helmholtz Zentrum
Munich, was incorporated to acquire the status of a German
private limited company (GmbH; https://www.infrafrontier.eu/
infrafrontier-research-infrastructure/organisation/infrafrontier-
gmbh). The formation of the INFRAFRONTIER GmbH is an interim
measure towards further development into a European Research
Infrastructure Consortium (ERIC), a dedicated legal entity devel-
oped for research infrastructures in the European Union [41]. Nota-
ble ERICs include the BBMRI ERIC (http://bbmri-eric.eu/) in
biobanking, and the European Advanced Translational Research
Infrastructure in Medicine (EATRIS; http://www.eatris.eu/index.
html) ERIC, in translational medicine. The stakeholders of ERICs
are states (not institutions) committed to stable funding of infra-
structures.
As INFRAFRONTIER coordinator, the Helmholtz Zentrum
Munich was awarded project funds from the national research
ministry to develop INFRAFRONTIER nationally, cover funding for
the GmbH shares, and to contribute to the IMPC. While there is yet
no EC funding for large-scale phenotyping efforts, and all IMPC
contributions remain nationally funded, the EC-ESFRI process and
establishment of the INFRAFRONTIER legal entity has helped a few
EU archives and mouse clinics to obtain visibility and funding.
Nevertheless, there remain challenges, notably with persuading
government agencies to provide long-term funding for infrastruc-
ture initiatives. It is also debatable whether the ERIC model can be
successfully exported to non-EU settings.
EMMA is a network of different national partners, who all
have to go back to their ministry for funding. Ministries are
used to giving project funding for four years. This INFRA-
FRONTIER process is transitioning from project funding to
co-funding, to get stable funding. INFRAFRONTIER is
used on a national level to trigger additional co-funding
and investment. That is a challenge because the admin-
istrators are used to project-based funding and don’t want
to commit themselves to giving you a couple of millions per
year over 10 years. [R#6]
There are relatively few successful examples of hybrid and
transnational models of funding for research infrastructures.
The Universal Protein Resource (UniProt) (http://www.uniprot.
org/help/about) for protein sequence and annotation data receives
most of its funding from the NIH, with additional contributions by
the Swiss Federal Government for the UniProt partner Swiss Insti-
tute of Bioinformatics and the European Molecular Biology Labo-
ratory (EMBL; http://www.embl.de/) [42]. The Worldwide ProteinData Bank (wwPDB; http://www.wwpdb.org) is a collaboration of
major protein data banks and repositories in Europe, Japan, and
the US, supported by numerous funding agencies [39].
The need to develop viable revenue-generation models for
archives
Our participants debated optimal revenue-generation models for
community archives. While funders insisted that the research com-
munity needs to develop long-term plans for archive sustainability
and revenue-generation, they offered no specifics for developing
such plans. Currently, most repositories charge for products and
services, with many attempting a cost-recovery model, which gen-
erally requires long-term subsidies from leading funders such as the
EC for EMMA and the NIH for the KOMP Repository. Deposits of
mouse-related research materials into EMMA are currently free of
charge, with costs subsidized from EC funding. In contrast, in
Canada, a repository manager described how lack of funding limits
distribution. Moreover, the repository’s ability to derive income
from deposited strains is limited by restrictions on onward distribu-
tion imposed by the original depositors.
EMMA deposits are free and users have to pay to get the
mice out. But the deposits are only free because the EC
funds all deposits. EMMA have funding to pay for their
staff, and the same staff deposit and distribute. In
Canada, we have no funding except potentially through
research grants. That just pays for deposit of lines by the
grant-holders. Unless we have ongoing funding the
resources aren’t accessible because we need staff to pull
it out of the freezer and send it off to people. We know if we
are not getting income from some strain. . . most of the lines
deposited are not for distribution. Occasional withdrawals
don’t sustain a repository. [R#2]
In the IMPC, the ES cells are concentrated in specific reposito-
ries. The federated, international nature of the resources raises
additional challenges for distribution and income.
Only two or three repositories have the ES cells. UC
[University of California] Davis [lead partner] of the
KOMP Repository has all the ES cells produced by the
KOMP program. The Helmholtz Center in Munich has
all or most ES cells produced by EUCOMM. Sanger has a
large number produced by EUCOMM and also by the
KOMP program. And NorCOMM has produced a few.
[R#7]
As costs of archiving, production, and quality control differ
between sites, charges paid by users also differ, for example,
between the KOMP Repository (https://www.komp.org/fees.php)
and European Mouse Mutant Cell Repository (EuMMCR) (https://
www.eummcr.org/faq#handling-fee). Repositories distributing
materials to for-profit users (e.g. the KOMP Repository) charge
those users additional licensing fees. There are obstacles to the
distribution of less-requested and unique lines from smaller re-
positories that may receive fewer user requests and lack the staff
and infrastructure of their larger and better-known counterparts.
As more nationally funded partners come on board, business and
funding models remain parochial, with no clear solutions for
distributing collections across partner archives.www.elsevier.com/locate/nbt 285
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not duplicated at multiple repositories, or both, may be lost
as there isn’t any mechanism for transferring collections
between repositories and very few national funders may
want to allocate budget to stock foreign repositories. [R#2]
Within the EU, the EMMA network seeks to minimize internal
competition by adopting a standard fee structure for distribution,
notwithstanding the variable costs of archiving and production
amongst EMMA partners (https://www.infrafrontier.eu/
procedures/emma-repository/emma-service-fees). A standard fee
structure is not easily achieved ‘given the quite different fixed operat-
ing costs and levels of subsidization in different geographical locations’
[R#2]. Moreover, in the EMMA case, users still bear shipping costs.
Variable, often considerable, shipping costs can lead to users
‘shopping locally’ [R#6], reinforcing the trend of parochialism that
runs counter to the ethos of the mouse commons.
A challenge to distribution was the delay in EUCOMM’s ability to
distribute ES cells to for-profit entities [11]. The delay was partly due
to potential intellectual property (IP) liabilities arising from the
mode of generation of the high-throughput resource, utilizing
multiple reagents and methods that may be subject to third party
IP rights. In the US, in contrast, an Authorization and Consent
provision in the funding agreement with the NIH, enabled by the
Federal Acquisition Regulations (FAR), in practice, immunized KOMP
members, as federal government contractors, from potential patent
infringement litigation [43]. Thus, the KOMP repository is free to
distribute materials to commercial users. This provision is peculiar
to US Federal Government contracts, discretionary, and unlikely to
be implemented in other jurisdictions. However, on 2 July 2014,
EUCOMM partners were able to address their distribution challenge
by licensing commercial mouse-model developer genOway [44],
which held or had secured licenses to third party IP, to distribute
EUCOMM resources to commercial users. The EUCOMM-genOway
agreement allows genOway to provide commercial users with the
rights to use EUCOMM’s existing archive of conditional knockout
models. In addition, users have a defined time frame in which to
access EUCOMM materials and generate their own knockouts.
Potential patent infringement is a multi-layered issue [10]. First,
public repositories and their academic users are open to legal
action. For example, in 2011 the NIH intervened with ‘Authoriza-
tion and Consent’ to protect JAX from a February 2010 lawsuit by
the Alzheimer’s Institute of America (AIA), a non-practising entity
[45]. The AIA had filed suit against JAX for allegedly profiting from
the distribution to academic researchers of mouse models carrying
the ‘Swedish mutation’ associated with early-onset Alzheimer’s
disease. The AIA held a US patent for the mutation [46], which has
since been invalidated [47]. The NIH intervention not only
shielded JAX from rent-seeking litigation but also ended the AIA’s
settlement-related demands that JAX divulge identities of
researchers who had received the mouse model and could have
been exposed to AIA lawsuits [45,46]. Second, commercial entities
purchasing research reagents carrying infringement liabilities also
become targets for litigation. Limits on distribution to for-profit
entities has implications for public repositories, which generally
charge for-profit users fees that are higher than for academic and
non-profit users, a tiered pricing model that yields somewhat
higher returns.286 www.elsevier.com/locate/nbtCommercial entities can access our lines under the same
MTA as academic or non-profit researchers. The difference
is that the academic customers pay less. We have obliga-
tions to the holders of the patents on the technology that we
use to generate our library. When we make a commercial
sale we have to pay them royalties from that. [R#1]
Funders’ responsibility for long-term support to archives
Repository managers emphasized that funders need to recognize
that their support to repositories represents large-scale cost savings
and efficiency gains. Archives enable researchers to spend their
constrained research funds on investigations rather than on mak-
ing reagents, housing live animals, and distributing them to
colleagues.
[One argument to make to funding agencies is] that we’re
really saving valuable resources that your funds have
helped pay for and we’re saving researchers grant money
because they don’t have to keep the animals as live mice.
[R#2]
Before these resources were developed, the individual inves-
tigators would have had to spend large chunks of their
funding on creating their own resources. They can now
spend most of their funds on scientific experimentation,
testing hypotheses and achieving outcomes. The resources
mitigate current financial constraints for hypothesis driven
science. [R#7]
Some funders were sceptical of providing long-term support to
archives, in particular, to those whose use declines as needs and
priorities change over time.
We can’t always be the ones sustaining resources. Some
resources are all the rage and then go out of fashion. We
need honest conversations about whether a resource is
something we’re hanging on to just because we invested
a lot in it, and we’re unsure if we’ve extracted all the value
from it, or whether it is essential and should be main-
tained. How much money or effort to keep it alive long
enough that it could re-emerge as something useful versus
just letting it die completely? [F#4]
However, repository managers felt that even successful reposi-
tories will still require supplementary funding support. For exam-
ple, while the successful KOMP repository no longer depends on
NIH funding, sustainability remains a concern because of the costs
associated with maintaining user satisfaction.
The KOMP repository, NIH funded for four years, is no
longer funded by the NIH. It needs to rely solely on income
derived from distribution of products to the research com-
munity. This has been a highly successful project, the first
and only NIH supported resource to go completely self-
sufficient. However, the repository needs to continue to
provide customer support, technical support, and a website
that is informative, helpful and useful so that people
continue to want to obtain these products. These are
absolutely necessary to derive income in order to maintain
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archive is easily sustainable in the long run, for decades to
come. [R#7]
Repository managers emphasized that few repositories can be-
come self-sustaining purely on the strength of distributional cost
recovery, even taking account of economies of scale [19]. Income
from high-demand strains may not be sufficient to subsidize
maintenance of strains in lower demand but with untapped po-
tential. Maintaining little-used strains is an important role for a
repository because research trends are unpredictable, and such a
strain may become an important resource in the future. External
funding therefore remains important to storing such strains; this
task falls on public repositories because it is not viable for com-
mercial repositories to maintain unpopular strains. For example,
there was a resurgence of interest in lines generated from the large-
scale, worldwide Ethyl Nitrosourea (ENU) mutagenesis pro-
grammes of the early 2000s. While thousands of ENU lines, each
unique, were archived, the difficulty of mapping candidate muta-
tions led to many lines being ‘left on ice’. Recently, however, next
generation sequencing techniques (NGS) have facilitated muta-
tion identification. Many centres are now re-sequencing archived
lines with a surge in new disease models, and importantly the
discovery of allelic2 series of mutations in genes already implicated
in diseases [48].
Obsolescence: new technologies and reagents may alter use of
repositories
Shifts in the community’s use of reagents (e.g. from gene trap lines
to conditional knockout strains) and model organisms (e.g. from
mice to rats) either have limited, or may limit, use of mouse
resources.
Our repository only has gene trap lines, which are out of
favour right now. Most customers prefer conditional knock-
outs because you can model closer to what usually happens
in vivo. You can direct effects in specific tissues and tailor
your experiments to your area of expertise. [R#1]
Mice are cheaper than rats, but rats are bigger animals. So
you can take larger samples from rats. The rat’s physiology
is more akin to the human. But we don’t have the trans-
genic technologies for rats that we have for mice. If rats
became more amenable to genetic manipulation then our
archive’s activity would diminish quite substantially.
[R#3]
The recent emergence of genome editing technologies may
present a new challenge to the viability and sustainability of
archives, especially those maintaining and distributing ES cell
lines. The technologies include Zinc Finger Proteins (ZFNs), Tran-
scription activator-like effector nucleases (TALENs) and most re-
cently, the CRISPR/Cas9 system (Clustered Regularly Interspaced
Short Palindromic Repeats and their CRISPR Associated protein 9)
[49]. Accessible in any laboratory with molecular biology experi-
ence and some animal expertise, these technologies enable ma-2 An allele is a form of a gene, found at a specific chromosomal locus.nipulation of genes in simple and complex experimental
organisms (including bacteria, mice and primates) and may allow
genomic alterations directly in embryos. Thus, researchers can
avoid the lengthy and unpredictable process of genetically modi-
fying ES cells, developing them into embryos and then into adult
organisms, which may or may not be able to transmit the altera-
tions to offspring. Some participants suggested that this advantage
of genome editing technologies could reduce reliance on ES cells
and their archives.
With ES cell manipulations, you still have a barrier to your
success and that is whether that ES cell can actually
contribute to the germline [‘germline competence’, or
ability to successfully contribute to gamete formation
and transmit targeted genes to progeny [50]]. Vertical
transmission is quite a hurdle. Now these other technolo-
gies are able to bypass the ES cell and directly modify the
genome in the embryo ensuring transmission. [R#7]
Precision targeted genome editing of mice in vivo will mean
that it’s no longer necessary to manipulate a stem cell to get
the mouse you need. We have lived off mouse stem cell
banking for a long time. That’s changing. [D#3]
While the KOMP repository distributes both mice and ES
cells, the EUCOMM repository, EUMMCR, only distributes
ES cells. This has implications for sustainability . . . with
the advent of CRISPR/CAS9, the demand for ES cells could
decrease. [R#2]
An alternate view was that the new technologies, with limited
targeting efficiency and relatively high associated costs, posed no
significant or immediate challenge to ES cell archives.
We have been able to work with ES cells in a very high
throughput fashion. With those new technologies, that
hasn’t been done satisfactorily yet. I don’t believe that
CRISPRs, TALENs, Zinc Fingers will reduce the value of
the current KOMP, EUCOMM and NorCOMM resources.
[R#7]
To make a mutant mouse from scratch with CRISPR/CAS9
and this genome editing technology may never get as cheap
as it is to pull a stem cell out of a freezer and then breed it
up. [D#3]
Despite enthusiasm for genome-editing technologies, off-target
effects (unwanted mutations elsewhere in the genome) are a
serious issue and may make the reagents irreproducible [51,52].
Participants were concerned that mice made ‘in house’ and not
distributed through repositories would not be subject to verifica-
tion of characteristics such as background strain, disease status,
and mutation identity, all tested by repositories. Interactions
amongst genetic background, disease status, and phenotypes are
amongst the most common reasons for failure of the same muta-
tion to generate the same phenotype. Where phenotypes are, for
example, weakly penetrant or subject to modifiers, mice with the
same edited mutation may give rise to disparate phenotypes for
often completely unknown reasons [53].www.elsevier.com/locate/nbt 287
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industry’ methods has several potential negative effects. It could
divert already scarce research funds to the costly and piecemeal
task of making reagents, which may have diminished quality and
standardization in comparison with reagents produced using
standard protocols in large resource-making efforts. Second, there
are potential costs and losses from storing those reagents in ill-
monitored and unstandardized small institutional freezers associ-
ated with contamination and damage.
The mouse and human genomes were sequenced not by
single laboratories doing part of a chromosome each but by
laboratories working in consortia in high-throughput pro-
jects. If someone said, ‘‘I’ll do this gene using ZFNs, and I’ll
get my mouse and I’ll study it,’’ they’d be returning to the
Dark Ages, when people were knocking out one gene at a
time in their individual labs. . . We need improved efficien-
cies on those new technologies to enable them to be high
throughput and then allow some big laboratories to use
those technologies to create new mutations, and then make
sure those resources are available to the broader commu-
nity. [R#7]
It’s easier to standardize in big science because it is an
economy of scale. People have to standardize a lot of their
stuff because they have to do the same thing repeatedly. If
you’re running a small institution with a few mice and
small experiments, you would not have needed to make an
investment to large-scale standardisation or infrastructure.
[D#1]
The university labs haven’t got the infrastructure or staff to
do the health monitoring which we have. [R#3]
Research groups deposit individualized reagents in archives at a
lower rate than the high-throughput projects because groups are
not mandated to do so, or because the quality of the reagent is not
high enough to pass the quality control standards of the reposito-
ry. Lack of deposit returns the community to the ‘bad old days’
where materials and data were not shared, behaviour that ironi-
cally led to institutional policies on data and materials sharing and
funder commitments to generation of high-throughput commu-
nity resources and support for archives. Lessons learned are that
widely dispersed resources lead to increased direct and marginal
costs for funding agencies for the distribution of reagents associ-
ated with publications, duplication of resources, and increased
mouse usage. The latter two effects counter the ethical experimen-
tation aims of reduction, replacement and refinement, or ‘3R’ [54].
Thus, these novel technologies may be disruptive not only to
archives but also to norms of open, reproducible and ethical
science.
Promoting the research community’s use of public archives
To be sustainable, archives must be valued and used by their
respective communities. Archives provide insurance against loss
of reagents and data, enable ethical maintenance and distribution
of experimental organisms, and facilitate distribution to third
parties. Our participants, however, described the under-use of288 www.elsevier.com/locate/nbtarchives as a serious challenge to their sustainability and offered
some solutions to enhance usage. Use in this context means both
deposit to, and withdrawal from, archives.
Challenges to the deposit of reagents and data
At the community level, concerns over publication priority [55]
and commercial interests in materials and data may inhibit deposit
or else prompt depositors to restrict the onward distribution of
materials by archives to third parties, especially for-profit entities.
Privacy and patient consent for human reagents are additional
concerns for deposit and use of biobanks.
When you start dealing with commercial interests or with
academics working with commercial interests, we can tell
them that we need data returned, but it won’t happen.
Also, I’ve dealt with projects where the researchers were
hesitant to deposit sequence data because they weren’t
done analysing it. But with such data you’re never done
analysing. At some point you need to let others look at it
too. [F#3]
However, practical impediments to deposit of data and materi-
als also exist, at the end of the depositing researchers and of the
receivers, that is, journals and archives. Archives generally require
depositors to perform pre-submission quality control of reagents
and data. Depositors may view such checks as onerous and avoid-
able investments of time, personnel, and funds. Database man-
agers also emphasized that researchers need to provide sufficient or
well-annotated metadata along with their data. Metadata is valu-
able background information about the provenance of study aims,
materials, and methods. By capturing the ‘tacit expertise’ in data
production, metadata enables other researchers to critically scru-
tinize and interpret experimental results and perform comparative
research using those reagents and data [56: 223].
Standard guidelines and quality control procedures exist for the
preparation and deposit of metadata. Thus, the project Minimum
Information about Biological and Biomedical Investigation
(MIBBI; http://mibbi.sourceforge.net/legacy.shtml) recommends
that researchers standardize descriptions of their experimental
protocols to ensure that other researchers can interpret these
protocols after accessing them online. The research design of a
small academic project may not require the organized compilation
of metadata, and researchers may not see a need to process
metadata for archiving. However, background information on
reagents acquires greater importance in the context of collabora-
tive research, wherein large datasets and the means and processes
of obtaining them need to be scrutinized, compared, and verified
amongst research groups in diverse sites. In the post-genomics era,
metadata acquires increased importance as data circulates across
increasingly larger and more diverse networks [56].
If you just buy a mouse and you’re interested in doing an
experiment and data integration isn’t your primary inter-
est, the strain background of the mouse is not part of your
experimental design. It is just something that comes with
the mouse knockout that you buy or that you make. But if
your experiment compared a mutant mouse strain with a
wild type mouse [standardised, but not genetically ma-
nipulated], it would be important to know both strain
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project, comparing mice across centres would be something
that highly motivated you. You would want to integrate a
mouse phenotype with information on the allele, informa-
tion on strain background and information on any map-
ping to a human disease if the mouse was a disease model.
[D#1]
However, the heterogeneity of the research community, with
diverse and changing experimental methods, instruments, and
reporting formats, precludes consensus about what metadata
should capture [56]. Metadata may be layered and complex, which
challenges current options for display in journals.
The journal model doesn’t support the complexity of the
data that we need to re-do or to fully understand the
experiment. Tables are just static representations of some
of the data. If data only comes to you from publication, it is
difficult to analyse the effects of extra variables that come
from the experimental design. [D#1]
The non-availability or lack of capacity of relevant archives is
also a significant challenge to deposits. While funders call for
public deposit of research output, funding shortfalls may lower
the actual availability of appropriate archives where output can be
sent. Also, the large volumes of data and materials being generated
are outstripping the available funding and storage capacity of
existing archives. In some cases, there are no funds to add capacity
to old archives or create and administer new archives for the
deposit of novel data and materials.
We went from the second to the fourth generation of
sequencers in about four years. That is accelerating the
research but the computing power and storage are getting
limiting. There is a value in keeping data because you can
find secondary and tertiary uses for it, but how do we keep
it? How long? Who pays for it? We can’t keep growing the
storage. All the National Science Foundation [NSF; US
funder] grants have conditions like open access, data
management plans, how the data will be preserved and
archived. Everybody is struggling on how to meet the NSF
regulations right now. [F#1]
Withdrawal of reagents and release of data – operational delays
and the challenge of managing user expectations
Archives need to be used not only for deposits but also for
onward distribution of data and materials to third parties.
Our interviews indicated areas for improvement in (i) the tech-
nical standardization and quality control of mouse strains and
associated data; and (ii) standardization of legal terms and
conditions for distribution through use of different forms of
licenses ranging from simple conditions of use to material
transfer agreements (MTAs). The lesson from the latter is to
keep legal terms as simple and as standard as possible to prevent
delays due to institutional negotiations over terms of withdraw-
al and use. Issues regarding the role of MTAs in archive gover-
nance are elaborated elsewhere [11,57]. Here, we focus on
factors in technical standardization that influence withdrawal
of reagents from repositories.In the case of the IMPC, resources are being accessed either on
the basis of a known gene or on the basis of an interesting
phenotype, related to the research being carried out by the inves-
tigator. The use of reagents such as mice, ES cells, and vectors is
connected to the quality of data on, for example, genotype,
background strain, and phenotype of the reagents. Access to these
data provides users with information on the contents of archives
so they can make informed decisions about withdrawals. Data-
bases thus have a significant mediating role in the uptake of
materials from repositories, and often ‘database curators have to
manually align information about each strain of mutants available
in stock centres with the online data actually available in relation
to those strains’ [58,34]. For an end-user attempting to locate a
mouse strain and associated data, such consolidation offers a
remedy to the current situation for mouse repositories, wherein
collections are both scattered and overlapping. In some cases
collections are mirrored for biosecurity, in other cases a single
strain may only be found at one site. Many valuable mouse strains
remain with individual laboratories and institutions. In that situ-
ation, databases and search portals (e.g. International Mouse
Strain Resource, IMSR; http://www.findmice.org/) facilitate access
by offering standardized information on the location and techni-
cal aspects of mouse strains, stocks, and mutant ES cell lines.
However, even with extensive standardization of search terms
and nomenclature associated with materials, users may have
variable understandings and misplaced expectations of IMPC
output and the related repository holdings.
With these complex IMPC alleles, folks don’t always
understand the nomenclature and what they will get. They
may want the conditional line when in fact we are distrib-
uting the knockout line that can be converted into a
conditional, which involves an additional breeding step.
The first hurdle is to make sure that the client understands
what genetic background the mouse is on. Many don’t
understand how versatile these alleles are or how one
actually gets from the initial knockout to the conditional
status. [R#3]
Archive managers also described delays that they felt were
inherent to the processes of preparing diverse forms of data for
release or for preparing reagents for shipping to customers. They
described the unfavourable reactions of some users to the inevita-
ble and prolonged waiting period entailed by quality control and
standardization.
Solutions to enhance deposits to archives
Participants described various incentives to enhance deposit.
Deposits that accord with the requirements of a funding agency
or journal could be an allowable grant expense [8]. Publishers
could expand available options for publishing, using, and citing
pre-publication data and experimental metadata [59]. Better
markers for proof of deposit, such as standardized accession
numbers, could be used as productivity measures for professional
advancement, ‘if, within your institution’s advancement criteria
data, depositing data has a beneficial effect on your annual review’
[F#3]. In bioinformatics, an accession number is a unique iden-
tifier assigned to a piece of data, for example, a sequence on its
submission to an archive, for example, GenBank or the Europeanwww.elsevier.com/locate/nbt 289
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updated, the accession number remains constant [60]. Accession
numbers can be provided in publications, providing proof of
deposit and enabling other researchers to locate, use, and cite the
resources in a manner analogous to previous research publica-
tions. Accession numbers are already used, for example, to prove
deposit of sequence data in GenBank prior to publication [61].
Citations are a key performance metric for academic researchers
and the prospect of getting such recognition of deposits may
incentivize depositors.
Archives also offer practical incentives to promote deposits.
Many researchers prefer to complete the peer review of their
research articles before submitting the relevant reagents and data
to public archives for community use [55]. Thus, some resources
offer moratoria on reagent and data release: ‘a grace period just in
case somebody is still working on a publication, at least two years where
the line is already archived but not yet visible to the external world’
[R#4]. Some archives incentivize deposits by offering conditional
refunds (e.g. the ‘Sharing Plan’ of the KOMP Repository; https://
www.komp.org/sharingplan.php) and by absorbing shipping costs
and offering credits on future purchases (e.g. the RIKEN BRC;
http://mus.brc.riken.jp/en/deposit).
Some participants suggested that incentives to deposit, while
essential, need to be complemented by the enforcement of data
and materials sharing policies. Funding agencies could withhold
funds for lack of adherence. For example, from November 2012,
the NIH has begun to seriously enforce its policies regarding open-
access publication and data deposit. Similarly, in March 2014, four
UK funders announced that, from 2016, the Research Excellence
Framework, a key audit for research funding, would consider only
open-access papers in online institutional archives [62]. Evidence
suggests that enforcement actions have raised the percentage of
papers placed in the NIH-supported PubMed Central database for
public access no later than a year after publication from 75% in
2012 to 82% in 2014. Similarly, The Wellcome Trust’s compliance
rate rose from 55% in 2012 to 69% in 2014 [62].
Lately NIH has been really cracking down and you won’t
get your grant renewal if your manuscripts aren’t open
access. When NIH do renewals they check if the PIs have
published and PIs have to provide the PubMed Central IDs
[PMCID] for their manuscripts3 [F#7]
Some funders expressed reservations about the feasibility of
enforcing sharing policies. While funders carefully review sharing
plans at the grant-application stage, they lack resources to monitor
actual deposits at project completion. The rapid pace of research
inhibits monitoring and enforcement. In many cases, quite rea-
sonably, data may not be published until a year or more after the
end of the grant; continuous monitoring for years after the end of a
project is unrealistic for funders. Additionally, monitoring of
output in ‘investigator initiated’ academic research is less stringent
than that observed in larger projects, such as the high-throughput
IKMC and IMPC, which operate under more strictly defined time-3 Peer-reviewed articles in the NIH-supported archive PubMed Central (PMC;
http://www.ncbi.nlm.nih.gov/pmc/) are assigned a digital identifier, the PMCID,
which NIH-funded researchers can cite to demonstrate compliance with the
NIH’s open-access publication requirements.
290 www.elsevier.com/locate/nbtlines, deliverables, and governance structures. Archive managers,
on the other hand, insisted that funders, in association with
publishers, have the gatekeeping power to track and enforce
compliance with data and materials sharing policies.
The funding agencies and journals have to start saying you
must, as a condition of receiving funding and or publishing
work, deposit research tools to a repository for anyone who
wants to access them. [R#2]
Archive managers were also keen for journals to enforce consis-
tent attribution of archives in publications. Attribution may in-
volve a direct identification of the source archive; or it may be
indirect and guide users to the archive through published acces-
sion numbers. Metrics derived from such attributions enable
objective assessment of archive usage and role in stimulating
research. Archives could use these metrics as evidence for their
funding requests. Unfortunately, archive managers lack funds,
personnel, and time to track or correct attributions in publica-
tions. Archive managers were resigned to attributions being omit-
ted, suggesting that omissions were due to word limits in journals
or to the superfluity of citing well-known reagents.
Some funders suggested that community education and encour-
agement to deposit, instead of enforcement, could generate cul-
tural changes conducive to sharing via public archives. Stringent
enforcement of sharing policies could drive a wedge between
funders and the research community. As members of funding
review panels are often themselves active researchers, they may
be reluctant to discipline their peers.
Each of CIHR’s 13 institutes has a scientific director with
an academic appointment. So they are still 50 per cent a
researcher. This model keeps funders embedded in the
research community, working closely with it, not divorced
from it. You want to maintain a good bidirectional flow of
information so that you remain well-grounded in the needs
and capabilities of the research community, while gently
instituting policies that are in everyone’s best interest. You
want community buy-in, not to be imposing rules. [F#2]
Archive managers also saw outreach to the community as key to
improving sharing practice and archive quality and use (e.g. TAIR’s
elicitation of user input to improve its search and visualization
tools) [63]. Unfortunately, only larger and better-funded archives
can employ personnel for large-scale outreach.
Discussion
Effective governance of archives requires considerations of sus-
tainability and remit, that is, that operations meet the objectives of
resource creators, funders, and users. Here, we discuss implications
of our findings and suggest lessons for other communities (e.g.
communities using non-murine models, or initiatives in biobank-
ing), struggling to develop, manage, and sustain research archives.
We discuss challenges and solutions for the governance of two
levels of archive activity (1) housing and distribution of research
reagents and data from large-scale, transnational, resource initia-
tives; and (2) deposit and withdrawal of resources generated by
individual research groups. Many archives support both levels of
activity.
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generation initiatives
The publicly funded IKMC and IMPC resources have been gener-
ated with considerable effort and expense at a time of increased
financial strain for community archives [1]. The resources provide
high-quality and accessible tools for basic and clinically relevant
research where animal models serve as surrogates for human
disease and are key tools for proof-of-concept studies. Wide utili-
zation of these and similar resources would justify past, ongoing,
and future investments in making and disseminating them. Re-
source uptake on a global scale will be influenced by the ability of
the archives to operate at the required efficiency, with implemen-
tation of appropriate legal and technical standards for resource
development, maintenance, and distribution. Our interviews in-
dicate, however, that mouse model archives require, but also lack,
stable funding to facilitate their long-term transnational opera-
tions and their role in supporting the global mouse research
commons.
Funders are limited in their ability to support research infra-
structure beyond the standard five-year funding cycle and national
jurisdictions. An emergent priority is therefore harmonized and
concerted action by national funders to support research infra-
structures with transnationally distributed resources and opera-
tions. EMBL, ELIXIR [16] and, more recently, Infrafrontier [40],
illustrate the implementation of some novel co-funding solutions
for research infrastructures. In all three cases governance mecha-
nisms are critical to the success of the infrastructures. ELIXIR and
Infrafrontier have adopted quite different structural and legal
models with interesting implications not only for these infrastruc-
tures but also for the viability of new or un-associated resources in
the communities outside their umbrellas.
EMBL, 40 years old in 2014, has an annual budget of around
s200M of which 50% is obtained from member and associated
member states on the basis of proportion of Net National Income
(NNI), in addition to ad hoc and special donations. EMBL is funded
under an international inter-governmental treaty complemented
by bilateral treaties, with tax and legal status implications, be-
tween EMBL and the countries that host its main laboratory and its
outstations such as EMBL-EBI in Hinxton UK. Following the ESFRI
initiative, Member States agreed to create ELIXIR, a dedicated
initiative to support the coordination, integration and sustainabil-
ity of Europe’s life science data resources. The foundation for
ELIXIR is the ELIXIR Consortium Agreement [64] and the Consor-
tium has adopted the legal personality provided by the EMBL
treaty. It is now formally a special project of EMBL [65]. ELIXIR
Hub funds are accounted for by EMBL, but EMBL does not control
spending or governance of ELIXIR and as such the entities remain
independent of each other. National contributions to the ELIXIR
Hub in Hinxton are based on NNI and are used in a variety of ways
to support the network, as described in ELIXIR’s recent financial
plan [66]. The Nodes, including EMBL-EBI which acts as the
‘‘European Node’’, are principally funded through national
sources (in the case of EMBL-EBI, EMBL direct funding) and
additionally raise external grant funding for their sustainability.
The ELIXIR Hub provides, amongst other services, training, strat-
egy development, resource integration, interoperability standards,
and support for the identification of sources of funding and
coordination of funding applications. Resources within ELIXIRmay benefit from funding from the Hub for development and
integration though ‘‘pilots’’ (https://www.elixir-europe.org/
about/pilot-projects) and in future ‘‘commissioned services’’,
where Nodes receive longer-term support to develop or maintain
services. Additionally, a set of databases will be highlighted as
‘‘core resources’’. This will apply to a small subset of what are
considered to be the most important databases for life science
users. They would be the focus of ELIXIR’s policy actions should
major sustainability issues arise.
ELIXIR’s legal identity allows it to compete for funding, for
example from Horizon 2020 from which it has been awarded a
major implementation grant starting in September 2015, illustrat-
ing how the coordination of national communities and resources
can help leverage additional funding at the EU level. ELIXIR thus
supports sustainability and development of the network of
resources in Europe without the intention of acting as a source
of long term direct funding for the operation of individual
resources, at least as currently envisioned.
The ELIXIR framework does not, however, offer the possibility
of support for resources outside its national Nodes, and adoption
as ELIXIR ‘‘named services’’ or eligibility for funding through pilot
actions. Any new resource will need to comply with ELIXIR quality
standards to be accepted as an ELIXIR named service, and it will
need to be associated with national ELIXIR Node and nationally
funded. This may be difficult for many useful new resources, either
because the originating groups may not be included in a national
ELIXIR Node, or lack of sufficient local funds to support the ELIXIR
quality criteria. This could have adverse implications for the
funding of novel and possibly key data resources from institutions
outside the ELIXIR umbrella, and makes national Node gover-
nance and national science funding policy critical in supporting
the richness of the data ecosystem necessary for a vibrant scientific
environment. The risk that national Nodes remain exclusive, or
that national funding agencies might use ELIXIR membership as a
criterion for local funding decisions, for example, could seriously
compromise the development of cutting edge science. This issue is
discussed at more length in Attwood et al. [67]. Applying an
ELIXIR model to bioresources may result in similar problems,
squeezing out the funding of small and niche resources that might
be crucial to particular, or novel, fields. The alternative however
would be transnational funding of individual national centres, but
the potential ceding of control of a national resource to an
international organization may be unacceptable to some countries
and rules of governance would be critical to viability.
The Infrafrontier model is based on a memorandum of under-
standing signed by Germany, France, Czech Republic, Finland,
Greece and the European Molecular Biology Laboratory (EMBL) for
the coordination of the pan-European activities of the research
infrastructure. Currently Infrafrontier has legal recognition in
Germany as a GmbH, but will in future use the ERIC legal instru-
ment. Through the Infrafrontier MoU national governments have
committed to the financial support of the national facilities con-
tributing to the international network of research infrastructures.
Infrafrontier functions therefore, like ELIXIR, mainly as a coordi-
nating project, with the national partners contributing funds in a
flexible way to allocation of national capacities to the Infrafrontier
Research Infrastructure, and provides value through coordination,
reducing duplication and pooling of expertise. It remains to bewww.elsevier.com/locate/nbt 291
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implemented outside Europe, given the heterogeneity and relative
inflexibility of national science policy contexts, funding priorities,
and legal environments.
Funders emphasized that archives need to shoulder the primary
responsibility for their own success and financial viability. How-
ever, archive managers countered that even when archives become
self-sustaining for daily operations (e.g. the KOMP Repository),
external public sector funding remains crucial for infrastructure
(e.g. equipment and estates), services, and long term sustainabili-
ty. Moreover, the plant archive TAIR experienced funding cuts
even with a record of high achievements [63]. TAIR consequently
resorted to charging for-profit, non-profit, and academic users for
access. Even with such a subscription model, TAIR can no longer
undertake some activities that added value to its data [68–70].
Moreover, adoption of subscription to raise revenues has draw-
backs [39]. Archive personnel have the onerous task of monitoring
users and ensuring payments. Grant-funded researchers, interna-
tionally facing budget constraints, may see subscription-based
access as a disincentive. Subscription lowers data integration as
paid-access databases may not share their data with free databases.
Tiered subscription models, with basic data sets openly accessible
and additional charges for enhanced data, tools, and services, are
neither tenable nor equitable. In addition, researchers may not
provide data to subscription-based databases if their funder stipu-
lates open-access publication. Non-contribution of new data
would depreciate quality and usage of databases over time, leading
perhaps to their closure.
With new disruptive technologies, such as gene editing, chal-
lenging the utility of ES cells in mouse research, funders need to
consider the long-term strategic value of their support to reposi-
tories, which will need to adapt to new technologies to retain user
bases and, more importantly, to disseminate novel but also stan-
dardized, reproducible, and affordable reagents to the wider com-
munity. It must be remembered that such public repositories serve
an important role for industry as well as for academic and non-
profit researchers. Moreover, the aims of public infrastructures are
distinct from those of purely commercial operations precisely
because they can hedge public investment in research against
novel uses and developments in enabling technologies.
Regarding income-generation models that archives can adopt,
key revenue pipelines can be opened by attracting industry users,
who may be asked to pay higher costs than their academic counter-
parts. However, the KOMP and EUCOMM experiences indicate
that for distribution to the commercial sector, resource developers
and distributing archives need external protections against rent-
seeking litigation by intellectual property rights (IPR) holders, who
may enforce claims on components of materials, methods, and
technologies used at various points in resource development
[10,11].
Governance of archives to support community-level research
activities
The governance of a research commons needs to ensure that
research tools are made available and accessible via archives
[7,9]. Archive use for deposits and withdrawals, coupled to public
attribution in peer-reviewed literature, facilitates accessibility of
reagents and data, non-duplicative research, experimental testing292 www.elsevier.com/locate/nbtof existing knowledge, and generation of new insights [1,2,8]. The
return contribution of secondary and tertiary data and materials
by end users enhances the value of the original resources and
facilitates the iterative process of knowledge testing and genera-
tion. Our data indicate a need for funders, archive managers, and
publishers to support research infrastructures via a coordinated
tripartite approach that (1) develops incentives for deposit of data
and materials into archives, (2) monitors and attributes deposits,
and (3) judiciously enforces policies for data and materials sharing
[8,59,71–73].
Compared to archive managers, funders and journal publishers
have the strategic positioning and authority to jointly translate
sharing agreements into community practice. An issue for further
investigation is the feasibility and acceptability of digital gover-
nance mechanisms to integrate the actions of funders, publishers,
and researchers to ensure sharing via the use of public archives. For
example, publishers may collate accession numbers for data and
material deposits, which could be made available to funders to
inform their reviews of project output and applications for grant
renewals. Simultaneously, peer reviewers of funding applications
could receive guidance from funders on how to assess such records
in a manner similar to assessment of peer-reviewed publications.
The expansion of formats and norms of publication and citation
could encourage researchers to share metadata, which are valuable
for experimental testing of published results. Researchers could
also be motivated to publicly deposit their data and materials if
institutions viewed related records as markers of productivity.
In addition, archives require attribution to build their visibility
to attract users and to measure and demonstrate their utility to
prospective funders. Journals may be instrumental in ensuring
attribution that points to published research reagents in archives.
Finally, following Ostrom and Hess [7] on ensuring compliance
with the rules of using the commons, funders need to appropri-
ately enforce sharing policies and send an unequivocal message
that publicly funded research reagents need to be made speedily
and widely accessible. Enforcement is also important to curb free
riders, or users who extract resources from the commons without
contributing anything in return. For example, a concern, particu-
larly of individual researchers, is competitors withdrawing depos-
ited strains and wresting scientific priority from the original
depositors; or industry using archived mouse models without
making adequate compensation. In the current scenario, however,
only a few powerful and influential funders (e.g. the NIH and the
Wellcome Trust) are ready to enforce compliance with sharing
policy. Any prospective transnational oversight of post-project
sharing of materials and data will need consistent action by the
relevant gatekeepers. While such actions are not yet very evident,
there is some recognition of their necessity.
Conclusion
Our analysis indicates an urgent need for the design and imple-
mentation of new policies to support community archives that
serve both large-scale, transnational resource projects and indi-
vidual research groups. While high-impact resources can be built
through strong leadership and project management, their long-
term accessibility and sustainability require supporting reforms in
funding and governance, implemented via the coordinated action
of archive managers, funders, journals, and research institutions.
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